Jubilant Pharmova Intrinsic Value
Jubilant Pharmova intrinsic value. Jubilant Pharmova (JUBLPHARMA) median intrinsic value is ₹886.75 from 9 valuation models (range ₹280–₹2333), vs current price ₹933.25 — -5.0% downside (Trading Near Calculated Value), margin of safety -5.2%. Browse Jubilant Pharmova annual reports for revenue, profit, balance sheet and cash flow data.
JUBLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Jubilant Pharmova intrinsic value across 9 models vs current price ₹933.25 — upside/downside and value range per method. Analyse JUBLPHARMA shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹279.97 | ₹223.98 - ₹335.96 | -70.0% | EPS: ₹7.88, Sector P/E: 22x |
| Book Value Method | asset | ₹2333.12 | ₹2099.81 - ₹2566.43 | +150.0% | Book Value/Share: ₹4435.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1866.50 | ₹1679.85 - ₹2053.15 | +100.0% | Revenue/Share: ₹5937.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1866.50 | ₹1679.85 - ₹2053.15 | +100.0% | EBITDA: ₹980.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2333.12 | ₹1866.50 - ₹2799.74 | +150.0% | CF Growth: 10.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹279.97 | ₹251.97 - ₹307.97 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹279.97 | ₹251.97 - ₹307.97 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹886.75 | ₹798.08 - ₹975.43 | -5.0% | EPS: ₹7.88, BVPS: ₹4435.00 |
| Dividend Yield Method | dividend | ₹279.97 | ₹251.97 - ₹307.97 | -70.0% | DPS: ₹5.00, Target Yield: 2.5% |
JUBLPHARMA Intrinsic Value vs Market Price — All Valuation Models
Jubilant Pharmova fair value range ₹280–₹2333 vs current market price ₹933.25 across 9 valuation models. For current market price and key ratios, visit JUBLPHARMA screener.
JUBLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Jubilant Pharmova median intrinsic value ₹886.75, current price ₹933.25 — Trading Near Calculated Value by 5.0%, margin of safety -5.2%.
What is the intrinsic value of JUBLPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jubilant Pharmova (JUBLPHARMA) is ₹886.75 (median value). With the current market price of ₹933.25, this represents a -5.0% variance from our estimated fair value.
The valuation range spans from ₹279.97 to ₹2333.12, indicating ₹279.97 - ₹2333.12.
Is JUBLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Jubilant Pharmova (JUBLPHARMA) appears to be trading near calculated value by approximately 5.0%.
JUBLPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Jubilant Pharmova financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 1.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JUBLPHARMA Cash Flow Quality — Operating & Free Cash Flow
Jubilant Pharmova operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,227 Cr | ₹656 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,072 Cr | ₹1,072 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹971 Cr | ₹673 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹661 Cr | ₹424 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹838 Cr | ₹677 Cr | Positive Free Cash Flow | 8/10 |